LOGAN, Utah — EchoStar Chairman Charles W. Ergen sang the praises of Inmarsat’s management and strategy but regretted that the two companies could not be combined through an EchoStar takeover at a time when the global satellite sector is badly in need of consolidation.
Ergen also regretted that Inmarsat’s convertible notes rewarded the note holders in proportion to the size of EchoStar’s offer, calling it a “semi-poison pill” that helped make the deal impossible by adding 10% to its cost.
In an EchoStar conference call with . . .
To view the entire article, become a subscriber!
